LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 983 | 3643 | 0.2715 | -0.2680 |
| SK-BR-3 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 1476 | 788 | 3643 | 0.2184 | -0.3826 |
| SK-BR-3 | AZD7762 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1505 | 3643 | 0.4110 | 0.0064 |
| SK-BR-3 | AZD7762 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 1351 | 3643 | 0.3693 | -0.0732 |
| SK-BR-3 | AZD7762 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1283 | 3643 | 0.3493 | -0.1140 |
| SK-BR-3 | AZD7762 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1052 | 3643 | 0.2870 | -0.2365 |
| SK-BR-3 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1004 | 3643 | 0.2744 | -0.2613 |
| SK-BR-3 | AZD7762 | 10 | uM | LJP6 | 72 | hr | 1476 | 1002 | 3643 | 0.2729 | -0.2658 |
| SK-BR-3 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1566 | 3643 | 0.4308 | 0.0464 |
| SK-BR-3 | AZD8055 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 1473 | 3643 | 0.4058 | -0.0006 |
| SK-BR-3 | AZD8055 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1474 | 3643 | 0.4052 | -0.0019 |
| SK-BR-3 | AZD8055 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1313 | 3643 | 0.3628 | -0.0839 |
| SK-BR-3 | AZD8055 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1322 | 3643 | 0.3635 | -0.0821 |
| SK-BR-3 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 1476 | 1074 | 3643 | 0.2955 | -0.2183 |
| SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3306 | 3643 | 0.9102 | 0.8639 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 3294 | 3643 | 0.9060 | 0.8564 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3427 | 3643 | 0.9437 | 0.9173 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 3608 | 3643 | 0.9909 | 0.9868 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 3504 | 3643 | 0.9626 | 0.9434 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 72 | hr | 1476 | 1730 | 3643 | 0.4786 | 0.1347 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 4189 | 3772 | 1.1105 | 1.1604 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3985 | 3772 | 1.0566 | 1.0829 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3773 | 3772 | 1.0002 | 0.9996 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3268 | 3772 | 0.8666 | 0.7982 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3146 | 3772 | 0.8339 | 0.7480 |